Stock Ratings / Health Care / HROW / earnings

MNKD (63) SPTX (56) CTY (61) AVLN (49) ⌘ Pro Terminal →

Harrow Inc. (HROW) Next Earnings Date & Expected ±10.2% Move

$29.99 +2.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Harrow Inc. (HROW) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (75% profit margin, 43% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $1.12B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HROW)Realized 20D OHLCV Swing Band: ±10.2%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10.2% Swing Band

±$3.06 Expected Swing

MODEL EARNINGS SETUP GAUGE

HROW Quantitative Pre-Earnings Setup: 71/100

Trailing EPS: $4.25 • YoY Revenue Growth: 36.4%

Model Bullish Setup (71/100)Model Risk Weight (29/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$272.3M	-$5.1M	$43.0M	75.1%
FY 2024	2024-12-31	$199.6M	-$17.5M	-$23.8M	75.3%
FY 2023	2023-12-31	$130.2M	-$24.4M	$3.8M	75.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating HROW & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on HROW
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HROW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.01%▼ DESCENDING CHANNEL

2026-10-30O $29.69H $30.05L $28.08C $29.99VOL 335.2K

RES: $34.75SUP: $26.78SMA50: $32.86SMA200: $38.35

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HROW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HROW Butterfly Map → + Track HROW →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

31.7%/yr Implied 5Y Growth

vs. +36.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HROW today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HROW. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HROW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HROW)

Health Care Rank #86 of 1016 ⚔️ MNKD vs HROW Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HROW vs. MNKD, SPTX, CTY, AVLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Harrow Inc. (HROW) ranks #86 by composite RQD confidence (71/100, grade B-) and #349 by equity capitalization ($1.12B). Within this direct 5-issuer industry benchmark cohort, HROW leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently leads its immediate peer cohort in composite quantitative strength at 71/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HROW ACTIVE Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	Benchmark Subject
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-hrow →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-hrow →
CTY City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	/cty-vs-hrow →
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-hrow →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001360214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harrow Inc. (HROW) reported GAAP revenue of $272.3M (+36.4% vs. FY2024 revenue of $199.6M , and +109.2% cumulative change since FY2023) , GAAP net income of -$5.1M, operating cash flow of $43.9M, and free cash flow of $43.0M (+280.6% YoY). On the balance sheet, HROW closed FY2025 with $399.5M in total assets against $0 in total debt (Altman Z-Score: 2.67, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$272.3M	-$5.1M	$43.9M	$43.0M	$399.5M	—
FY2024 (FY)	2024-12-31	$199.6M	-$17.5M	-$22.2M	-$23.8M	$389.0M	—
FY2023 (FY)	2023-12-31	$130.2M	-$24.4M	$3.8M	$3.8M	—	—

3. HROW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HROW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Harrow Inc. (NASDAQ: HROW) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $29.99 (+2.04% 1D, market cap $1.12B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, HROW ranks #86 in composite RQD confidence.

How does HROW compare to MNKD and SPTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HROW carries a Roarable B- (71/100 RQD), trailing P/E of N/A, gross margin of 75.1%, and ROIC of 42.9%. By comparison, MNKD (MannKind Corporation) holds a C grade (63/100 RQD, P/E N/A, ROIC 54.5%, cap $1.13B) and SPTX (Seaport Therapeutics Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, HROW leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HROW?

Per HROW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001360214), Harrow Inc. generated $272.3M in revenue (+36.4% YoY), -$5.1M in net income, and $43.0M in free cash flow against $399.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (75% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HROW trading relative to its 50-day, 200-day, and 52-week technical levels?

HROW last traded at $29.99 (+2.04% on volume of 321,095 shares), positioning the stock -8.73% below its 50-day simple moving average ($32.86) and -21.80% below its 200-day simple moving average ($38.35). Across its 52-week range of $26.96 to $54.85, HROW sits at the 10.9% percentile with a 14-day RSI of 38.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($26.93 to $33.05).